Fresenius Kabi registered solid growth in Q3, thanks in part to a successful roll-out of biosimilars including most prominently the firm’s Tyenne (tocilizumab) biosimilar rival to Actemra/RoActemra, the German giant has reported.
Biosimilars Roll-Out Propels Fresenius Kabi’s Growth
Firm Credits Biosimilars Contribution As Increases Seen In Q3
As Fresenius delivered its third-quarter results, the firm’s Fresenius Kabi division celebrated sales growth of two-thirds in its Biopharma biosimilars segment amid several solid increases seen in Q3.
More from Earnings
More from Products
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).
• By
Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
With an ambitious goal to file a biosimilar to the world-renowned Botox brand via the US FDA’s 351(k) regulatory pathway, AEON Biopharma has revealed the latest steps in its plan.